More Visualization, Better Surgeries

Enabling effective resections with a novel cancer detection platform.

THE STATUS QUO

Resections Fall Short.

Resections are the most common treatment for cancer, but they face re-excision rates of 30-50%. While every cancer cell can increase these odds, surgeons can't see cancer on the cellular level.

Mechanism of Action

THE TECHNOLOGY

Run By Microscopy,
Powered By AI.

LightIR is the world's first device that combines microscopy with deep learning, letting it condense the diagnostic accuracy of pathology labs into a handheld probe. It is expected to head to market by 2023.

Mechanism of Action

research and development

News & Updates

Enabling The Cancer
Surgeries Of The Future

Our most up-to date article covering the extent of re-excisions and LightIR as a surgical intervention.

Read on Medium

IR-V1: Explainer Pitch

An academic-style document highlighting the technicals of our latest biopsy testing venture.

Watch on YouTube

HSNRI Lab Secured

In March of 2021, we received interest from the Health Science North Research Institute to gather data on tumour samples.

Learn More at HSNRI

Don't Wait. Join Us.

LightIR is a constant work in progress, and we can't get there without your support. If you believe in our mission, please get in touch.